Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 2. Approaches To Eliminate Opioid Agonist Metabolites via Modification of Linker and 4-Methoxycarbonyl-4-phenylpiperidine Moiety
- 27 October 1999
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (23) , 4778-4793
- https://doi.org/10.1021/jm990201h
Abstract
We have previously described compound 1a as a high-affinity subtype selective α1a antagonist. In vitro and in vivo evaluation of compound 1a showed its major metabolite to be a μ-opioid agonist, 4-methoxycarbonyl-4-phenylpiperidine (3). Several dihydropyrimidinone analogues were synthesized with the goal of either minimizing the formation of 3 by modification of the linker or finding alternative piperidine moieties which when cleaved as a consequence of metabolism would not give rise to μ-opioid activity. Modification of the linker gave several compounds with good α1a binding affinity (Ki = < 1 nM) and selectivity (>300-fold over α1b and α1d). In vitro analysis in the microsomal assay revealed these modifications did not significantly affect N-dealkylation and the formation of the piperidine 3. The second approach, however, yielded several piperidine replacements for 3, which did not show significant μ-opioid activity. Several of these compounds maintained good affinity at the α1a adrenoceptor and selectivity over α1b and α1d. For example, the piperidine fragments of (+)-73 and (+)-83, viz. 4-cyano-4-phenylpiperidine and 4-methyl-4-phenylpiperidine, were essentially inactive at the μ-opioid receptor (IC50 > 30 μM vs 3 μM for 3). Compounds (+)-73 and (+)-83 were subjected to detailed in vitro and in vivo characterization. Both these compounds, in addition to their excellent selectivity (>880-fold) over α1b and α1d, also showed good selectivity over several other recombinant human G-protein coupled receptors. Compounds (+)-73 and (+)-83 showed good functional potency in isolated human prostate tissues, with Kbs comparable to their in vitro α1a binding data. In addition, compound (+)-73 also exhibited good uroselectivity (DBP Kb/IUP Kb > 20-fold) in the in vivo experiments in dogs, similar to 1a.Keywords
This publication has 10 references indexed in Scilit:
- Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 3. Approaches To Eliminate Opioid Agonist Metabolites by Using Substituted Phenylpiperazine Side ChainsJournal of Medicinal Chemistry, 1999
- Design and Synthesis of Novel α1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic HyperplasiaJournal of Medicinal Chemistry, 1998
- Characterization of specific binding of L-762,459, a selective α1A-adrenoceptor radioligand to rat and human tissuesEuropean Journal of Pharmacology, 1998
- Discovery of .alpha.1a-Adrenergic Receptor Antagonists Based on the L-Type Ca2+ Channel Antagonist NiguldipineJournal of Medicinal Chemistry, 1995
- Spiropiperidines as high-affinity, selective .sigma. ligands.Journal of Medicinal Chemistry, 1992
- High prevalence of benign prostatic hypertrophy in the communityThe Lancet, 1991
- The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptorNature, 1988
- Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortexNature, 1983
- HETEROGENEITY OF HISTAMINE Hi‐RECEPTORS: SPECIES VARIATIONS IN [3H]MEPYRAMINE BINDING OF BRAIN MEMBRANESJournal of Neurochemistry, 1979
- Metathesis of 1-alkeneThe Journal of Organic Chemistry, 1976